These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 15324519

  • 1. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
    Leonardi A, Zafirakis P.
    Curr Med Res Opin; 2004 Aug; 20(8):1167-73. PubMed ID: 15324519
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM, Tekelioglu Y, Turk A, Akyol N.
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC.
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS.
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB, Greiner JV.
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [Abstract] [Full Text] [Related]

  • 9. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL.
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [Abstract] [Full Text] [Related]

  • 13. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
    Endre L, Hidasi V.
    Orv Hetil; 2006 Sep 10; 147(36):1741-3. PubMed ID: 17087018
    [Abstract] [Full Text] [Related]

  • 14. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN, Luna JD, Discepola M.
    Acta Ophthalmol Scand Suppl; 2000 Sep 10; (230):64-5. PubMed ID: 11057355
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB.
    Ann Allergy Asthma Immunol; 1998 Sep 10; 81(3):211-8. PubMed ID: 9759796
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
    Butrus S, Greiner JV, Discepola M, Finegold I.
    Clin Ther; 2000 Dec 10; 22(12):1462-72. PubMed ID: 11192137
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ.
    Clin Ther; 2003 Jul 10; 25(7):1975-87. PubMed ID: 12946545
    [Abstract] [Full Text] [Related]

  • 19. [Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis].
    Haicl P, Cerná H.
    Cesk Slov Oftalmol; 2004 Sep 10; 60(5):362-7. PubMed ID: 15566225
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.